Alpha Cognition Inc V.ACOG

Primary Symbol: C.ACOG Alternate Symbol(s): ACOGF

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

CSE:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Apr 08, 2022 4:19pm

164 Views

Post# 34589203

Recent News

If you missed it $ACOG.v $ACOGF recently announced positive preclinical data from their ALPHA-0602 ALS gene therapy program.

The results further support the development of ALPHA-0602 for the treatment of the motor neuron degeneration associated with ALS.

This is a big step in $ACOG ‘s progression and strongly supports the continued development of ALPHA-0602 for the treatment of ALS. IMO one to keep an eye on.

https://www.businesswire.com/news/home/20220329005271/en/

<< Previous

Bullboard Posts

Next >>

Nvidia! Turnaround for Nel, Saturn Oil & Gas, Lufthansa, TUI?